rethinkTHC Search
Menu
Study breakdown

Brain Scans Reveal How the Endocannabinoid System Changes in Psychiatric Disorders

Narrative ReviewModerate evidence
The takeaway

A review of PET imaging studies shows that the brain's endocannabinoid system is altered in cannabis use disorder, alcoholism, PTSD, schizophrenia, and eating disorders — each in distinct ways.

Neuroscience enthusiasts, mental health researchers, and anyone curious about how the brain's endocannabinoid system relates to psychiatric conditions.

What the researchers found

PET imaging reveals distinct alterations in endocannabinoid system components across psychiatric conditions. The review summarizes available PET tracers targeting CB1 receptors, FAAH, MAGL, and other ECS components, and their findings across cannabis use disorder, alcohol use disorder, PTSD, schizophrenia, and eating disorders.

Why it matters

PET imaging allows researchers to see the endocannabinoid system working in living brains for the first time. Understanding how this system changes in different psychiatric disorders could lead to more targeted cannabinoid-based treatments.

The numbers in context

Disorders covered: cannabis use disorder, alcohol use disorder, PTSD, schizophrenia, eating disorders. ECS components imaged: CB1 receptors, FAAH, MAGL, and others. Multiple PET tracers reviewed for each target.

How the study worked

Narrative review of PET tracer development and clinical application studies. Covers multiple ECS-targeting radiotracers and their use in diverse psychiatric populations. Synthesizes findings across different ECS components and disorders.

What this study cannot tell us

Narrative review format (not systematic). PET studies typically have small sample sizes and are expensive. Most tracers are still research tools, not clinically available. Cross-study comparison is complicated by different tracers and methods.

How to read the evidence

Comprehensive narrative review of an emerging imaging field, but individual PET studies tend to be small and methodology varies.

When this study was published

Published in 2026, capturing the latest advances in endocannabinoid system PET imaging.

The bigger picture

The endocannabinoid system is emerging as a common thread across multiple psychiatric disorders, but each condition shows unique patterns of disruption. This suggests cannabinoid-based treatments may need to be tailored to specific disorders rather than using a one-size-fits-all approach.

Questions still open

  • Can ECS PET imaging become a diagnostic tool for psychiatric disorders? Would these imaging findings help select which patients might benefit from cannabinoid therapies? How do ECS changes progress over time in each disorder?

Common questions

Can brain scans show how cannabis affects the brain?
Yes — PET scans can now image the endocannabinoid system in living brains, showing how CB1 receptors and related enzymes change with cannabis use and in various psychiatric disorders.
Is the endocannabinoid system involved in mental health conditions?
This review shows distinct ECS alterations in cannabis use disorder, alcoholism, PTSD, schizophrenia, and eating disorders — suggesting it plays a role in multiple psychiatric conditions, though in different ways.

Read the original research

PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.

Neuroscience bulletin, 42(2), 419-438

Citation

Cui, Chunyi; Dou, Xiaofeng; Cen, Peili; Jin, Chentao; Wang, Jing; Niu, Jiaqi; Xue, Chenxi; Tian, Mei; Zhang, Hong; Zhong, Yan. (2026). PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.. Neuroscience bulletin, 42(2), 419-438. https://doi.org/10.1007/s12264-025-01515-z

Explore the wider topic